Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Share-based Compensation of $2.7 million for Q4 2025, up 126.66% year-over-year from $1.2 million in Q4 2024, and down 84.12% quarter-over-quarter from $17.3 million in Q3 2025.
Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Share-based Compensation history runs 16 years deep, the most recent figure standing at $2.7 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 126.66% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $4.4 million (up 150.55% YoY), while the FY2025 annual figure was $12.7 million, up 19.92% from the prior year.
- Share-based Compensation for Q4 2025 stood at $2.7 million, down from $17.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $17.3 million in Q3 2025, with the low at -$10.3 million in Q4 2024.
- The 5-year median for Share-based Compensation is $769500.0 (2022), against an average of $1.4 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 633.16% in 2024, then soared 10849.37% in 2025.
- Rigel Pharmaceuticals' Share-based Compensation stood at $2.3 million in 2021, then soared by 74.43% to $4.1 million in 2022, then slumped by 52.62% to $1.9 million in 2023, then sank by 633.16% to -$10.3 million in 2024, then surged by 126.66% to $2.7 million in 2025.
- Business Quant data shows RIGL's Share-based Compensation at $2.7 million in Q4 2025, $17.3 million in Q3 2025, and $418000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 6.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.84 Mn |
| Jun 30, 2026 | 6.84 Mn |
| Mar 31, 2026 | 3.46 Mn |
| Mar 31, 2026 | 3.46 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 17.30 Mn |
| Sep 30, 2025 | 17.30 Mn |
| Jun 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Sep 30, 2024 | 158,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |